Compare TH & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | VIR |
|---|---|---|
| Founded | 1978 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2017 | 2019 |
| Metric | TH | VIR |
|---|---|---|
| Price | $16.60 | $8.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $16.50 | ★ $19.43 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,635,000.00 | $68,556,000.00 |
| Revenue This Year | $17.45 | $270.22 |
| Revenue Next Year | $38.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.97 | $4.16 |
| 52 Week High | $18.93 | $11.66 |
| Indicator | TH | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 41.89 |
| Support Level | $6.50 | $8.48 |
| Resistance Level | $18.83 | $10.10 |
| Average True Range (ATR) | 0.56 | 0.43 |
| MACD | -0.31 | -0.04 |
| Stochastic Oscillator | 23.47 | 20.96 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.